April 15, 2024

SNMMI's CDMRP Report Language Approved

President Joe Biden signed H.R. 2882, the second FY 2024 appropriations package titled Further Consolidated Appropriations Act, 2024 into law. The signing of this bill completed the FY 2024 appropriations process.

In 2023, SNMMI worked closely with Congress for legislative language that increases recognition for the value of diagnostic and therapeutic nuclear medicine research in federal agencies, with a particular focus on the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP). The language also encourages the Director of the CDMRP to emphasize nuclear medicine in research funding opportunities to further drive the development of precision imaging and advanced targeted therapies.

SNMMI is excited to share that with the signing H.R. 2882, which included the FY 2024 Defense Appropriations bill, SNMMI’s CDMRP report language has been approved. Below is the CDMRP report language in both the House and the Senate:

House:

• Nuclear Medicine. -- The Committee is encouraged by innovation in the field of nuclear medicine research and the potential of precision medicine through the use of novel diagnostic imaging and targeted radiotherapy. To enhance the development of precision imaging and advanced targeted therapies while creating medical and economic efficiencies, the Committee encourages the Director of the Congressionally Directed Medical Research Programs to include nuclear medicine imaging and related techniques in descriptions of funding opportunities, where relevant, to support early diagnosis, enhance treatment, and improve outcomes for servicemembers and their families.

Senate:

• Nuclear Medicine. -- The Committee is encouraged by innovative advances in the field of nuclear medicine research, and the potential to fully realize the promise of precision medicine through the use of novel diagnostic imaging and targeted radiotherapy. Advanced nuclear imaging procedures use disease-specific positron emission tomography [PET] radiopharmaceuticals to identify the presence and magnitude of therapeutic targets in patients with Alzheimer's and Parkinson's disease, advanced cardiac disease, and prostate, breast, neuroendocrine and brain cancer, among others. Innovative nuclear medicine improves diagnostic and targeted treatment capabilities through non-invasive techniques that provide information that cannot be acquired through other imaging technologies. The Committee encourages the Director of the Congressionally Directed Medical Research Programs to include nuclear medicine imaging and related techniques in descriptions of funding opportunities, where relevant, to support early diagnosis, enhanced treatment and outcomes of active duty servicemembers and their families to drive the development of precision imaging and advanced targeted therapies while creating medical and economic efficiencies.

The inclusion of SNMMI’s CDMRP report language is a positive step for the nuclear medicine community. Moving forward, SNMMI has a goal of increasing federal funding for nuclear medicine research and development.